Jason Melear
Overview
Explore the profile of Jason Melear including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2025 Mar;
16(1):2242.
PMID: 40050276
No abstract available.
2.
Lee H, Ramchandren R, Friedman J, Melear J, Melear J, Flinn I, et al.
Blood
. 2024 Dec;
145(3):290-299.
PMID: 39622165
Treatment options for stage I/II bulky and advanced-stage disease have recently extensively changed. For decades in North America, ABVD (doxorubicin hydrochloride [Adriamycin], bleomycin sulfate, vinblastine sulfate, and dacarbazine) has been...
3.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2023 Aug;
14(1):4741.
PMID: 37550302
No abstract available.
4.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2023 Jul;
14(1):4444.
PMID: 37488191
Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we...
5.
Yimer H, Melear J, Faber E, Bensinger W, Burke J, Narang M, et al.
Leuk Lymphoma
. 2022 Jun;
63(10):2383-2392.
PMID: 35730586
In the primary analysis of LYRA, daratumumab + cyclophosphamide/bortezomib/dexamethasone (DARA + CyBorD) was effective and well tolerated in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). We report...
6.
Yimer H, Melear J, Faber E, Bensinger W, Burke J, Narang M, et al.
Br J Haematol
. 2019 Mar;
185(3):492-502.
PMID: 30828799
This United States community study evaluated the combination of daratumumab, bortezomib, cyclophosphamide and dexamethasone (D-VCd) in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). Patients received 4-8 induction...